| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
N/A |
| Shares
Out: |
61,150,000 |
| Market
Cap: |
6.68(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$113.49 - $145.93 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Jazz Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medicines for patients with serious diseases with limited or no options. Co.'s primary marketed products are: Xyrem® (sodium oxybate) oral solution, for the treatment of both cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Xywav™ (calcium, magnesium, potassium, and sodium oxybates) oral solution, for the treatment of cataplexy or EDS in narcolepsy patients seven years of age and older; and Sunosi® (solriamfetol), to improve wakefulness in adult patients with EDS associated with narcolepsy or obstructive sleep apnea.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
12,000 |
12,000 |
12,000 |
| Total Buy Value |
$0 |
$1,435,800 |
$1,435,800 |
$1,435,800 |
| Total People Bought |
0 |
1 |
1 |
1 |
| Total Buy Transactions |
0 |
1 |
1 |
1 |
| Total Shares Sold |
5,000 |
8,704 |
24,601 |
181,935 |
| Total Sell Value |
$548,250 |
$986,699 |
$3,178,219 |
$26,303,629 |
| Total People Sold |
1 |
2 |
12 |
19 |
| Total Sell Transactions |
1 |
3 |
19 |
67 |
| End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Mcgill Iain |
SVP, Europe & Rest of World |
• – – |
2016-02-29 |
4 |
D |
$121.58 |
$95,440 |
D/D |
(785) |
21,969 |
|
- |
|
| Hooper Suzanne Sawochka |
EVP & General Counsel |
• – – |
2016-02-26 |
4 |
D |
$125.00 |
$91,875 |
D/D |
(735) |
43,912 |
|
- |
|
| Cox Russell J. |
EVP & COO |
• – – |
2016-02-26 |
4 |
D |
$125.00 |
$91,375 |
D/D |
(731) |
66,959 |
|
- |
|
| Young Matthew P. |
EVP & CFO |
• – – |
2016-02-26 |
4 |
D |
$125.00 |
$92,125 |
D/D |
(737) |
36,223 |
|
- |
|
| Mcgill Iain |
SVP, Europe & Rest of World |
• – – |
2016-02-26 |
4 |
D |
$125.00 |
$49,000 |
D/D |
(392) |
22,754 |
|
- |
|
| Miller Michael Patrick |
SVP, US Commercial |
• – – |
2016-02-26 |
4 |
D |
$125.00 |
$58,625 |
D/D |
(469) |
18,992 |
|
- |
|
| Wilson Karen J |
SVP, Finance & PAO |
• – – |
2016-02-26 |
4 |
D |
$125.00 |
$35,625 |
D/D |
(285) |
26,742 |
|
- |
|
| Cozadd Bruce C |
Chairman & CEO |
• • – |
2016-02-26 |
4 |
D |
$125.00 |
$325,875 |
D/D |
(2,607) |
310,289 |
|
- |
|
| Hooper Suzanne Sawochka |
EVP & General Counsel |
• – – |
2016-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
9,000 |
44,647 |
|
- |
|
| Cox Russell J. |
EVP & COO |
• – – |
2016-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
9,000 |
67,690 |
|
- |
|
| Young Matthew P. |
EVP & CFO |
• – – |
2016-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
9,000 |
36,960 |
|
- |
|
| Mcgill Iain |
SVP, Europe & Rest of World |
• – – |
2016-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
4,000 |
23,146 |
|
- |
|
| Miller Michael Patrick |
SVP, US Commercial |
• – – |
2016-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
19,461 |
|
- |
|
| Wilson Karen J |
SVP, Finance & PAO |
• – – |
2016-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
3,300 |
27,027 |
|
- |
|
| Cozadd Bruce C |
Chairman & CEO |
• • – |
2016-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
31,000 |
312,896 |
|
- |
|
| Treacy Paul |
SVP, Technical Operations |
• – – |
2016-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
4,000 |
15,454 |
|
- |
|
| Mulligan Seamus |
Director |
– • – |
2016-02-23 |
4 |
AS |
$120.68 |
$3,431,904 |
D/D |
(27,968) |
1,102,579 |
|
- |
|
| Miller Michael Patrick |
SVP, US Commercial |
• – – |
2016-02-16 |
4 |
AS |
$115.63 |
$11,563 |
D/D |
(100) |
13,461 |
|
- |
|
| Enright Patrick G |
Director |
– • – |
2016-02-10 |
4 |
S |
$114.43 |
$1,179,214 |
I/I |
(10,000) |
4,323 |
|
- |
|
| Cozadd Bruce C |
Chairman & CEO |
• • – |
2016-02-09 |
4 |
AS |
$111.37 |
$278,425 |
D/D |
(2,500) |
281,896 |
|
- |
|
| Miller Michael Patrick |
SVP, US Commercial |
• – – |
2016-01-15 |
4 |
AS |
$122.66 |
$12,266 |
D/D |
(100) |
13,561 |
|
- |
|
| Cozadd Bruce C |
Chairman & CEO |
• • – |
2016-01-12 |
4 |
AS |
$123.81 |
$309,525 |
D/D |
(2,500) |
284,396 |
|
- |
|
| Enright Patrick G |
Director |
– • – |
2016-01-05 |
4 |
S |
$137.71 |
$1,380,890 |
I/I |
(10,000) |
4,519 |
|
- |
|
| Miller Michael Patrick |
SVP, US Commercial |
• – – |
2015-12-15 |
4 |
AS |
$136.99 |
$13,699 |
D/D |
(100) |
13,661 |
|
- |
|
| Cozadd Bruce C |
Chairman & CEO |
• • – |
2015-12-08 |
4 |
AS |
$139.72 |
$349,300 |
D/D |
(2,500) |
286,855 |
|
- |
|
881 Records found
|
|
Page 27 of 36 |
|
|
0.37 (0.34%) 
